

**Fellow Publications/Presentations
January through December 2019**

Publications

1. **Khouri J**, Samaras C, Valent J, et. al. Monoclonal Gammopathy of Undetermined Significance: A Primary Care Guide. *Cleve Clin J Med.* 86 (1), 39-46. Jan 2019. PMID: 30624183
2. **Khouri J**, Kin A, Thapa B, et. al. Daratumumab Proves Safe and Highly Effective in AL Amyloidosis. *Br J Haematol.* 185 (2), 342-344. Apr 2019. PMID: 29938774
3. **Khouri J**, Reu F, Majhail N, et. al. Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma. *Clin Lymphoma Myeloma Leuk.* e374-e376. PMID: 31053548
4. **Madanat Y**, Kalaycio M, Nazha A. Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018? *Acta Med Acad.* 48 (1), 35-44. Apr 2019. PMID: 31264431
5. **Madanat Y**, Gerds A. Can Allogeneic Hematopoietic Cell Transplant Cure Therapy-Related Acute Leukemia? *Best Pract Res Clin Haematol.* 32 (1), 104-113. Mar 2019. PMID: 30927969
6. **Chakraborty R**, Sidana S, Shah G, et. al. Patient-Reported Outcomes With Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. *Biol Blood Marrow Transplant.* 25 (5), e155-e162. May 2019. PMID: 30500439
7. **Chakraborty R**, Majhail N, Anwer F. Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions? *JAMA Oncol.* June 2019 [Online ahead of print]. PMID: 31246229
8. **Chakraborty R**, Liu H, Rybicki L, et. al. Progression With Clinical Features Is Associated With Worse Subsequent Survival in Multiple Myeloma. *Am J Hematol.* 94 (4), 439-445. Apr 2019. PMID: 30663805
9. **Chakraborty R**, Rybicki L, Tomer J, et. al. Patient-reported Outcomes in Systemic AL Amyloidosis With Functional Assessment of Cancer Therapy-General (FACT-G) and Patient-Reported Outcomes Measurement Information System-Global Health (PROMIS-GH) in a Real-World Population. *Leuk Lymphoma*, 60 (14), 3544-3551. Dec 2019. PMID: 31272258
10. **Fallah J**, Rini B. HIF Inhibitors: Status of Current Clinical Development. *Curr Oncol Rep.* 21 (1), 6. Jan 22, 2019. PMID: 30671662
11. **Fallah J**, Olszewski A, et. al. Diagnostic and Therapeutic Splenectomy for Splenic Lymphomas: Analysis of the National Cancer Data Base. *Hematology.* 24 (1), 378-386. Dec. 2019. PMID: 30885066
12. **Hu R**, Winter A, Hill B. The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma. *Curr Oncol Rep*, 21 (5), 44. Apr 2019. PMID: 30941515

13. **Kishtagari A**, Jha B, Maciejewski J. TET2 Mutations and Clonal Dynamics. *Oncotarget*. 10 (21), 2010-2011. Mar 2019. PMID: 31007843
14. Durrani J, Awada H, **Kishtagari A**, et. Large Granular Lymphocytic Leukemia Coexists With Myeloid Clones and Myelodysplastic Syndrome. *Leukemia*. Oct 2019. PMID: 31624375
15. Saygin C, **Kishtagari A**, Cassaday R. Therapy-related Acute Lymphoblastic Leukemia Is a Distinct Entity With Adverse Genetic Features and Clinical Outcomes. *Blood Adv*. 3 (24), 4228-4237. Dec 2019. PMID: 31869410
16. Durer C, Durer S, **Lee S**. Treatment of Relapsed Multiple Myeloma: Evidence-based Recommendations. *Blood Rev*. 39, 100616. Jan 2020. PMID: 31500848
17. Barot S, **Lee S**, Patel B, et. al. Ibrutinib Is Effective in Refractory Type II Cryoglobulinemia. *Clin Lymphoma Myeloma Leuk*. 19 (12), e629-e632. Dec 2019. PMID: 31585822
18. **Patil P**, Shepherd F, Johnson D, et. al. A Career in Lung Cancer: Pushing Beyond Chemotherapy. *Am Soc Clin Oncol Educ Book*. 39, 583-589. Jan 2019. PMID: 31099660
19. **Patil P**, Hobbs B, Pennell N. The Promise and Challenges of Deep Learning Models for Automated Histopathologic Classification and Mutation Prediction in Lung Cancer. *J Thorac Dis*. 11 (2), 369-372. Feb 2019. PMID: 30962976
20. **Sheng I**, Rini B. Immunotherapy for Renal Cell Carcinoma. *Expert Opin Biol Ther*. 19 (9), 897-905. Sep 2019. PMID: 31173514
21. **Sheng I**, Kruse K, Leininger K, et. al. Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC). *Case Rep Oncol Med*. 2019, 6246209 eCollection. Jun 2019. PMID: 31281697
22. **Nizam A**, Aragon-Ching J. Frontline Immunotherapy Treatment With Nivolumab and Ipilimumab in Metastatic Renal Cell Cancer: A New Standard of Care. *Cancer Biol Ther*. 20 (1), 6-7. 2019. PMID: 30332546
23. Aragon-Ching J, **Nizam A**, Henson D. Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. *Clin Genitourin Cancer*. 17 (6), 436-442. Dec 2019. PMID: 31445851

Poster Presentations/Abstracts

1. **Chakraborty R**, et. al. Conditional survival in patients with Multiple Myeloma undergoing upfront Autologous Stem Cell Transplant. *Transplant & Cellular Therapy Meetings of ASBMT & CIBMTR*. February 2019. (Poster)
2. **Chakraborty R**, et. al. Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapse Multiple Myeloma. *ASH Annual Meeting*. December 2019. (Poster)

3. **Fallah J**, et. al. Correlation of myeloid-derived suppressor cells (MDSC) with pathologic complete response (pCR), recurrence free survival (RFS), and overall survival (OS) in patients with urothelial carcinoma (UC) undergoing cystectomy. Genitourinary Cancer Symposium. Sanfrancisco, CA. February 2019 (Poster)
4. **Fallah J**, et. al. Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC). Genitourinary Cancer Symposium. Sanfrancisco, CA. February 2019 (Poster)
5. **Fallah J**, et. al. Circulating cell free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC). ASCO Annual Meeting. Chicago, IL. June 2019. (Poster)
6. **Fallah J**, et. al. Association of cell-free DNA (cfDNA) levels with myloid-derived suppressor cells (MDSC) levels in blood of patients (pts) with muscle invasive (MI) and metastatic (met) bladder cancer (BC). ASCO Annual Meeting. Chicago, IL. June 2019. (Poster)
7. **Fallah J**, et. al. Safety and efficacy of bevacizumab plus TTFIELDS in patients with recurrent glioblastoma (GBM): data from a phase II clinical trial. Society for Neuro-Oncology Annual Scientific Meeting. Phoenix, AZ. November 2019.
8. **Hu R**, et. al. Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis. Orlando, FL. ASH Annual Meeting. December 2019. (Poster)
9. **Kishtagari A**, et. al. TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins. ASH Annual Meeting. December 2019 (Poster)
10. **Kishtagari A**, et. al. Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity. ASH Annual Meeting. December 2019 (Poster)
11. **Lee S**, Rosko N, Patel B, et. al. Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Primary Refractory AL Amyloidosis. 6th Annual Global Summit Hematologic Emergencies. British Columbia, CA. March 2019. (Poster)
12. **Lee S**, Rosko N, Samaras C, et. al. Improving time to initiation of bone modifying agents in patients with newly diagnosed multiple myeloma. ASCO Annual Meeting. Chicago, IL. May 2019. (Poster)
13. **Madanat Y**, Mukherjee S, Patel B, et. al. Intra-risk group heterogeneity in Myelodysplastic Syndromes. Acute Leukemia Forum. Newport Beach, CA. April 2019. (Oral)
14. **Madanat Y**, Sekeres M, Mukherjee S, et. al. Genomic Biomarkers Can Predict Response/Resistance to Lenalidomide in Non-Del (5q) Myelodysplastic Syndromes. Acute Leukemia Forum. Newport Beach, CA. April 2019. (Oral)

15. **Patil, P**, Khorrami K, Zagouras A, et. al. Novel CT Based Radiomic Features Are Prognostic and Predictive of Benefit of Chemoimmunotherapy in Advanced Non-Squamous NSCLC. 2019 World Conference on Lung Cancer. Barcelona, Spain. September, 2019. (**Oral**)
16. **Patil, P**, Jia X, Hobbs B, et. al. The Impact of Early Steroids on Clinical Outcomes in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors – A Cancerliq Cohort. 2019 World Conference on Lung Cancer. Barcelona, Spain. September, 2019. (Poster)
17. **Sadaps M**, et. al., A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer. 2019 Gastrointestinal Cancers Symposium. San Francisco, CA. January 2019 (Poster)
18. **Sadaps, M**, et. al. Precision Oncology in Pancreatobiliary Cancers: A Longitudinal Study. United European Gastroenterology Week (UEG) 2019. UEG Annual Meeting. Barcelona, Spain. October 2019. (**Oral**)
19. **Sadaps, M**, et. al. A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer. United European Gastroenterology Week (UEG) 2019. UEG Annual Meeting. Barcelona, Spain. October 2019. (**Oral**)
20. **Sadaps, M**, et. al. Tumor Size Increases the Risk for Lymph Node Metastases in T1b Esophageal Adenocarcinoma. United European Gastroenterology Week (UEG) 2019. UEG Annual Meeting. Barcelona, Spain. October 2019. (Poster)
21. **Sheng I**, et. al. Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS). Genitourinary Cancer Symposium. Sanfrancisco, CA. February 2019 (Poster)
22. **Sheng I**, et. al. Implications of the United States Preventative Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration. ASCO Annual Meeting. Chicago, IL. June 2019 (Poster)
23. **Sussman T**, et. al. Clinical Outcomes in Melanoma Patients with Family or Personal History of Cancer. Society for Melanoma Research 16th International Congress. Salt Lake City, UT. November 2019 (Poster)
24. **Sussman T**, et. al. Incidence and Outcome of Venous Thromboembolism in Melanoma Patients on Immunotherapy Stratified by Presence of Brain Metastases. Society for Melanoma Research 16th International Congress. Salt Lake City, UT. November 2019 (Poster)